Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

Next Previous
Trial Profile

A Randomized, Multicenter, Phase 3 Study Comparing Carfilzomib, Lenalidomide, and Dexamethasone (CRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed Multiple Myeloma

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Carfilzomib (Primary) ; Dexamethasone; Dexamethasone; Lenalidomide
  • Indications Multiple myeloma
  • Focus Registrational; Therapeutic Use
  • Acronyms ASPIRE
  • Sponsors Amgen; Onyx Pharmaceuticals

Most Recent Events

  • 01 Oct 2022 Results of post-hoc pooled analysis assessing cardiovascular risk factors and cardiovascular disease data from four clinical studies: ASPIRE, ARROW, FOCUS, ENDEAVOR published in the Clinical Lymphoma, Myeloma & Leukemia
  • 08 Dec 2020 Results assessing eligibility criteria of 6 landmark multiple myeloma studies (SPIRE, TOURMALINE-MM1, POLLUX, ELOQUENT-2, CASTOR and ENDEAVOR), presented at the 62nd Annual Meeting and Exposition of the American Society of Hematology.
  • 10 Dec 2019 Results comparing the cost per progression-free survival (PFS) for each of the comparators from the perspective of the Brazilian private healthcare system using PFS values based on POLLUX, ASPIRE, TOURMALINE MM1 and ENDEAVOR trials presented at the 61st Annual Meeting and Exposition of the American Society of Hematology

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top